Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Evolving Treatments Seek to Address Unanswered Questions in Hematologic Malignancies

November 16th 2022

Novel agents such as momelotinib and pacritinib are expanding the myelofibrosis treatment landscape, and additional research will further define the options available for patients with this disease, as well as those with other leukemias and lymphomas.

Dr. Perl on Genetic Testing and Targeted Therapies in AML

November 10th 2022

Alexander E. Perl, MD, MS, associate professor, medicine, the Hospital of the University of Pennsylvania, discusses why genetic testing is important for determining targeted therapies for patients with acute myeloid leukemia.

Lunning Lends Insight on Pivotal Data From Pan Pacific Lymphoma 2022

November 10th 2022

In this inaugural episode, Dr Lunning details important findings to come out of the Pan Pacific Lymphoma Conference, including results evaluating prophylactic medications in the management of patients with hematologic malignancies receiving cellular therapy or autologous stem cell transplant.

FDA Approves Brentuximab Vedotin for Pediatric Patients With Previously Untreated, High-risk Hodgkin Lymphoma

November 10th 2022

The FDA has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide in pediatric patients aged 2 years and older with previously untreated, high-risk classical Hodgkin lymphoma.

Novel Agents Replace CAR T-Cell Therapy in Later-Line, Relapsed/Refractory DLBCL

November 9th 2022

New treatments are emerging for patients with relapsed/refractory diffuse large B-cell lymphoma in addition to chimeric antigen receptor T-cell therapy, which has moved up into the second line.

Frontline Setting Boasts Multiple Treatment Options for Patients With ALL

November 9th 2022

Clinicians treating patients with newly diagnosed acute lymphocytic leukemia now have multiple options at their disposal, including tyrosine kinase inhibitors, blinatumomab, and multiagent chemotherapy-based regimens, with more options aiming to enter the treatment paradigm.

CAR T-Cell Therapies Improve Treatment Landscape in Relapsed/Refractory Multiple Myeloma

November 8th 2022

The increasing integration of CAR T-cell therapies into the treatment paradigm for adult patients with relapsed or refractory multiple myeloma addresses several unmet needs and improves outcomes for this historically limited patient population.

Sauter and Hill Talk Through CAR T-Cell Sequencing and Access in Lymphomas

November 7th 2022

Drs Sauter and Hill discuss the use of CAR T-cell therapy in patients with lymphomas, the potential for allogeneic CAR T cells, and ways to expand access and address financial toxicity.

Azacitidine-Based Combinations Represent New Treatment Possibilities in MDS

November 2nd 2022

Mikkael A. Sekeres, MD, MS, discussed the changes to the classifications of MDS, the evolution of targeted therapies for patients with acute myeloid leukemia, and approaches for patients with bone marrow failure syndromes.

First Patient Dosed With Menin Inhibitor BMF-219 in COVALENT-101 Trial in CLL

November 1st 2022

The first patient in the chronic lymphocytic leukemia cohort has been dosed in the phase 1 COVALENT-101 trial, which is evaluating the first-in-class covalent menin inhibitor BMF-219.

FDA Grants Fast Track Designation to MT-101 for CD5+ Relapsed/Refractory PTCL

October 31st 2022

The FDA has granted a fast track designation to MT-101 for use as a potential therapeutic option in patients with relapsed or refractory, CD5-positive peripheral T-cell lymphoma.

Iomab-B Conditioning Elicits Durable CR in Relapsed/Refractory AML

October 31st 2022

Reduced-intensity conditioning treatment plus Iomab-B prior to bone marrow transplant led to a durable and statistically significant 6-month complete remission rate vs conventional care in older patients with active, relapsed/refractory acute myeloid leukemia.

Women in Oncology: Leaving Passionate Legacies

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the scientific achievements they have witnessed in the field of leukemia and their hopes for the future of treating this disease.

Women in Oncology: The Value of Female Leadership

October 28th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss how they turned career obstacles into opportunities and what they have learned from being women in the leukemia field.

Cilta-cel Induces Strong Response in Chinese Patients With Relapsed/Refractory Multiple Myeloma

October 28th 2022

Ciltacabtagene autoleucel produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma treated at 8 sites in China.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

FDA Grants Priority Review to Quizartinib for Newly Diagnosed FLT3-ITD–Positive AML

October 24th 2022

The FDA has accepted and granted priority review to the new drug application for quizartinib in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, and as continuation monotherapy following consolidation, for the treatment of newly diagnosed adult patients with FLT3-ITD–positive acute myeloid leukemia.

Dr. Chen on FLASH Trial Results in CTCL

October 21st 2022

Pei-Ling Chen, MD, PhD, gives her perspective on results from the phase 3 FLASH trial investigating synthetic hypericin in CTCL.

Dr. Chen Explores Possible Genomic Basis for Racial Disparities in CTCL Outcomes

October 21st 2022

Pei-Ling Chen, MD, PhD, discusses genomic findings that may explain poorer outcomes for Black patients with CTCL.